ایجاد انقلابی در ایمونوتراپی سرطان با واسطه نانوذرات از طریق پیشرفت‌های مهندسی ژنتیک

Bray F, Laversanne M, Weiderpass E, et al. (2021) The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127(16), 3029-3030.
Chow A, Perica K, Klebanoff CA, et al. (2022) Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol 19(12), 775-790.
Darragh LB, Karam SD (2022) Amateur antigen‐presenting cells in the tumor microenvironment. Mol Carcinog 61(2), 153-164.
Das P, Ghosh S, Ashashainy V, et al. (2023) Augmentation of anti-proliferative efficacy of quercetin encapsulated chitosan nanoparticles by induction of cell death via mitochondrial membrane permeabilization in oral cancer. Int J Biol Macromol 250, e126151.
Deng Z, Tian Y, Song J, et al. (2022) mRNA vaccines: The dawn of a new era of cancer immunotherapy. Front Immunol 13, 1-15.
Duan Z, Luo Y (2021) Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 6(1), 1-21.
Duffy MJ, O'Grady S, Tang M, et al. (2021) MYC as a target for cancer treatment. Cancer Treat Rev 94, 1-7.
Gong N, Sheppard NC, Billingsley MM, et al. (2021) Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol 16(1), 25-36.
Isser A, Livingston NK, Schneck JP (2021) Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomater 268, 1-50
Li L, Miao Q, Meng F, et al. (2021) Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy. Theranostics 11(12), 6033-6043.
Li P, Jia L, Bian X, et al. (2023) Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities. Curr Treat Options Oncol 1, 1-17.
Li YR, Zhou Y, Kramer A, et al. (2021) Engineering stem cells for cancer immunotherapy. Trends Cancer 7(12), 1059-1073.
Lichter AS (2021) The treatment of breast cancer with excision followed by radiation therapy. Breast Cancer Collab Mgmt 137-156, CRC Press. 
Lin M, Yang Z, Yang Y, et al. (2022) CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today 42.
Liu S, Galat V, Galat Y, et al. (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14, 1-17.
Marofi F, Abdul‐Rasheed OF, Rahman HS, et al. (2021) CAR‐NK cell in cancer immunotherapy; A promising frontier. Cancer Sci 112(9), 3427-3436.
Raskov H, Orhan A, Christensen JP, et al. (2021) Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 124(2), 359-367.
Sušac L, Vuong MT, Thomas C, et al. (2022) Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC. Cell 185(17), 3201-3213.
Yang P, Meng M, Zhou Q (2021) Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. Biochimica et Biophysica Acta (BBA)- Rev Cancer 1876(1), 1-9.